Literature DB >> 32000949

Pittsburgh B Compound Positron Emission Tomography in Patients With AL Cardiac Amyloidosis.

Seung-Pyo Lee1, Hoon-Young Suh2, Sohyun Park2, Sera Oh2, Soon-Gu Kwak1, Hyue-Mee Kim3, Youngil Koh4, Jun-Bean Park1, Hyung-Kwan Kim1, Hyun-Jai Cho1, Yong-Jin Kim1, Inho Kim4, Sung-Soo Yoon4, Jeong-Wook Seo5, Jin-Chul Paeng2, Dae-Won Sohn6.   

Abstract

BACKGROUND: It remains unknown whether the noninvasive evaluation of the degree of amyloid deposition in the myocardium can predict the prognosis of patients with light chain (AL) cardiac amyloidosis.
OBJECTIVES: The purpose of this study was to demonstrate that 11C-Pittsburgh B compound positron emission tomography (11C-PiB PET) is useful for prognostication of AL cardiac amyloidosis by noninvasively imaging the myocardial AL amyloid deposition.
METHODS: This study consecutively enrolled 41 chemotherapy-naïve AL cardiac amyloidosis patients. The amyloid deposit was quantitatively assessed with amyloid P immunohistochemistry in endomyocardial biopsy specimens and was compared with the degree of myocardial 11C-PiB uptake on PET. The primary endpoint was a composite of all-cause death, heart transplantation, and acute decompensated heart failure.
RESULTS: The degree of myocardial 11C-PiB PET uptake was significantly higher in the cardiac amyloidosis patients compared with normal subjects and correlated well with the degree of amyloid deposit on histology (R2 = 0.343, p < 0.001). During follow-up (median: 423 days, interquartile range: 93 to 1,222 days), 24 patients experienced the primary endpoint. When the cardiac amyloidosis patients were divided into tertiles by the degree of myocardial 11C-PiB PET uptake, patients with the highest PiB uptake experienced the worst clinical event-free survival (log-rank p = 0.014). The degree of myocardial PiB PET uptake was a significant predictor of clinical outcome on multivariate Cox regression analysis (adjusted hazard ratio: 1.185; 95% confidence interval: 1.054 to 1.332; p = 0.005).
CONCLUSIONS: These proof-of-concept results show that noninvasive evaluation of myocardial amyloid load by 11C-PiB PET reflects the degree of amyloid deposit and is an independent predictor of clinical outcome in AL cardiac amyloidosis patients.
Copyright © 2020 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  cardiac amyloidosis; positron emission tomography; prognosis

Mesh:

Substances:

Year:  2020        PMID: 32000949     DOI: 10.1016/j.jacc.2019.11.037

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  9 in total

1.  Radiotracers to Address Unmet Clinical Needs in Cardiovascular Imaging, Part 2: Inflammation, Fibrosis, Thrombosis, Calcification, and Amyloidosis Imaging.

Authors:  John C Stendahl; Jennifer M Kwan; Darko Pucar; Mehran M Sadeghi
Journal:  J Nucl Med       Date:  2022-07       Impact factor: 11.082

2.  Independent Prognostic Utility of 11C-Pittsburgh Compound B PET in Patients with Light-Chain Cardiac Amyloidosis.

Authors:  You-Jung Choi; Youngil Koh; Hyun-Jung Lee; In-Chang Hwang; Jun-Bean Park; Yeonyee E Yoon; Hack-Lyoung Kim; Hyung-Kwan Kim; Yong-Jin Kim; Goo-Yeong Cho; Dae-Won Sohn; Jin-Chul Paeng; Seung-Pyo Lee
Journal:  J Nucl Med       Date:  2021-12-16       Impact factor: 11.082

Review 3.  The utility of positron emission tomography in cardiac amyloidosis.

Authors:  Subha Saeed; Jean Michel Saad; Ahmed Ibrahim Ahmed; Yushui Han; Mouaz H Al-Mallah
Journal:  Heart Fail Rev       Date:  2021-11-07       Impact factor: 4.654

Review 4.  Nuclear Imaging for Cardiac Amyloidosis: Bone Scan, SPECT/CT, and Amyloid-Targeting PET.

Authors:  Jin Chul Paeng; Joon Young Choi
Journal:  Nucl Med Mol Imaging       Date:  2021-01-07

Review 5.  Imaging-Guided Treatment for Cardiac Amyloidosis.

Authors:  Adam Ioannou; Rishi Patel; Julian D Gillmore; Marianna Fontana
Journal:  Curr Cardiol Rep       Date:  2022-05-07       Impact factor: 3.955

6.  18F-florbetaben positron emission tomography detects cardiac involvement in systemic AA amyloidosis.

Authors:  Maria Papathanasiou; Alexander Carpinteiro; Tim Hagenacker; Ken Herrmann; Tienush Rassaf; Christoph Rischpler; Peter Luedike
Journal:  Eur J Nucl Med Mol Imaging       Date:  2020-05-20       Impact factor: 9.236

Review 7.  Nuclear Imaging for the Diagnosis of Cardiac Amyloidosis in 2021.

Authors:  Weijia Li; Dipan Uppal; Yu-Chiang Wang; Xiaobo Xu; Damianos G Kokkinidis; Mark I Travin; James M Tauras
Journal:  Diagnostics (Basel)       Date:  2021-05-30

Review 8.  Cardiac Amyloidosis: Multimodal Imaging of Disease Activity and Response to Treatment.

Authors:  Rishi K Patel; Marianna Fontana; Frederick L Ruberg
Journal:  Circ Cardiovasc Imaging       Date:  2021-06-15       Impact factor: 8.589

Review 9.  The Role of Multi-modality Imaging in the Diagnosis of Cardiac Amyloidosis: A Focused Update.

Authors:  Shaun Khanna; Ivy Wen; Aditya Bhat; Henry H L Chen; Gary C H Gan; Faraz Pathan; Timothy C Tan
Journal:  Front Cardiovasc Med       Date:  2020-10-30
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.